Beijing Continent Pharmaceutical Co, Ltd.

This phase 3 trial tests if pirfenidone capsules can improve lung function in people with pneumoconiosis, a lung disease caused by inhaling dust. About 272 adults with silicosis or coal worker's pneumoconiosis will receive either the drug or a placebo for 52 weeks. The main goal …

This study tests whether high doses of hydronidone capsules are safe for people with liver scarring (fibrosis) or cirrhosis caused by chronic hepatitis B. About 300 adults will take the drug three times daily for 28 days and be monitored for side effects. The goal is to see if th…

This study tests the safety of a drug called hydronidone in 200 adults with liver scarring (fibrosis) caused by chronic hepatitis B or fatty liver disease. Participants take three capsules three times a day for 28 days. The main goal is to track any side effects that occur during…

This study tests a new drug called F573 in people with liver injury or liver failure. The goal is to see if it is safe and how it affects the body. About 97 adults will take part, and half will get the drug while the other half gets a placebo. The study focuses on safety and does…

This study tests a drug called hydronidone in 150 adults with liver scarring caused by chronic hepatitis B. Participants take the capsules three times daily for 28 days. The main goal is to check for side effects and ensure the drug is safe. This is an early-phase trial focused o…

This study tests if the drug pirfenidone can help people with lung injury caused by radiation therapy, with or without additional lung inflammation from immunotherapy. About 298 adults aged 18-75 with certain cancers who received chest radiation are being recruited. The trial com…

This study tests a single dose of hydroxynidone, an experimental drug for liver scarring, in 56 adults with mild to severe kidney problems and healthy volunteers. Researchers want to see how the drug moves through the body and if it is safe when kidneys are not working well. The …

This early-stage study tests a new medicine called F230 in 136 healthy adults to see if it is safe and how the body processes it. The drug is designed to treat pulmonary hypertension, a serious lung condition. Researchers will also check if food changes how the drug works. No dir…